Wedbush Research Analysts Lift Earnings Estimates for CATX

Perspective Therapeutics, Inc. (NYSE:CATX) – Analysts at Wedbush raised their Q1 2025 earnings estimates for Perspective Therapeutics in a research report issued on Wednesday, March 26th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.31) for the quarter, up from their previous estimate of ($0.37). Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($1.63) EPS and FY2027 earnings at ($1.73) EPS.

A number of other research firms have also issued reports on CATX. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. Finally, Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Trading Down 8.0 %

CATX stock opened at $1.96 on Monday. The firm has a 50-day moving average of $2.88 and a two-hundred day moving average of $6.10. Perspective Therapeutics has a 12 month low of $1.90 and a 12 month high of $19.05.

Insider Buying and Selling at Perspective Therapeutics

In related news, Director Robert F. Williamson III bought 22,192 shares of the company’s stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the acquisition, the director now owns 70,837 shares of the company’s stock, valued at approximately $160,799.99. This trade represents a 45.62 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Juan Graham purchased 33,333 shares of the firm’s stock in a transaction on Friday, March 28th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the purchase, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at $79,546.50. This represents a 1,649.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 115,696 shares of company stock valued at $256,344 over the last 90 days. 3.52% of the stock is owned by insiders.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CATX. Intech Investment Management LLC purchased a new stake in Perspective Therapeutics during the third quarter worth about $137,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after purchasing an additional 298,778 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Perspective Therapeutics by 8.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock worth $274,000 after buying an additional 1,672 shares during the period. FMR LLC lifted its holdings in Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Perspective Therapeutics by 1,302.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after buying an additional 44,174 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.